2,851
edits
Nicotinamide Mononucleotide (NMN): Difference between revisions
Nicotinamide Mononucleotide (NMN) (view source)
Revision as of 06:15, 17 November 2023
, 17 November 2023→Potential Benefits
| Line 110: | Line 110: | ||
! colspan="2" |Results of published human clinical trials | ! colspan="2" |Results of published human clinical trials | ||
|- | |- | ||
| style="border:none;" | [[File:NMN NAD+ Mice.png|frameless|100px]] | | style="vertical-align:top; border:none;" | <br>[[File:NMN NAD+ Mice.png|frameless|100px]] | ||
| style="border-left: none;" | | | style="vertical-align:top; border-left: none;" | | ||
* '''Brain''': improved brain function, protected from neurodegeneration^55,82,83,92,103, enhanced new myelin generation^80 | * '''Brain''': improved brain function, protected from neurodegeneration^55,82,83,92,103, enhanced new myelin generation^80 | ||
* '''Lung''': prevented pulmonary fibrosis, improved respiratory system function^33 | * '''Lung''': prevented pulmonary fibrosis, improved respiratory system function^33 | ||
| Line 122: | Line 122: | ||
* '''Skin''': protected the skin from photodamage caused by UVB irradiation^86 | * '''Skin''': protected the skin from photodamage caused by UVB irradiation^86 | ||
* '''Reproduction''': improved oocytes quality^88, increased the number of sperm^85 | * '''Reproduction''': improved oocytes quality^88, increased the number of sperm^85 | ||
| style="border:none;" | [[File:NMN NAD+ Human.png|frameless|100px]] | | style="vertical-align:top; border:none;" | <br>[[File:NMN NAD+ Human.png|frameless|100px]] | ||
| style="border:none;" | | | style="vertical-align:top; border:none;" | | ||
* '''Safety''': basically safe under the existing intervention dose and time^35,36,118,122,140,141,145-147,178 | * '''Safety''': basically safe under the existing intervention dose and time^35,36,118,122,140,141,145-147,178 | ||
* '''Sleep quality''': no significant improvement^35,118 | * '''Sleep quality''': no significant improvement^35,118 | ||